Trials / Conditions / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

30 registered clinical trials studyying Human Epidermal Growth Factor 2 Negative Carcinoma of Breast — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) NCT07222215	Kristina A. Fanucci	Phase 2
Recruiting	Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and A NCT06348134	University of Chicago	Phase 2
Not Yet Recruiting	Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer NCT06470672	Fudan University	Phase 2
Recruiting	A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957	NiKang Therapeutics, Inc.	Phase 1
Not Yet Recruiting	Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. NCT06338644	Helwan University	—
Terminated	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921	NiKang Therapeutics, Inc.	Phase 1
Recruiting	Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced C NCT05735080	Incyclix Bio	Phase 1 / Phase 2
Completed	Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - R NCT06463626	Novartis	—
Completed	PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) NCT03809988	MedSIR	Phase 2
Completed	WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 I NCT03854903	Georgetown University	Phase 1
Unknown	A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic NCT03854617	Chinese Academy of Medical Sciences	Phase 2
Completed	Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breas NCT02668666	Oana Danciu, MD	Phase 2
Completed	Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant NCT02894398	iOMEDICO AG	Phase 2
Completed	Palbociclib With Everolimus + Exemestane In BC NCT02871791	Dana-Farber Cancer Institute	Phase 1 / Phase 2
Completed	ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism NCT02806817	Centro Nacional de Investigaciones Oncologicas CARLOS III	EARLY_Phase 1
Terminated	Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer NCT02824575	Montefiore Medical Center	Phase 1
Terminated	A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older NCT02823262	Beth Israel Deaconess Medical Center	N/A
Active Not Recruiting	A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cance NCT02623972	Dana-Farber Cancer Institute	Phase 2
Unknown	Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer NCT02404051	Consorzio Oncotech	Phase 3
Completed	Patterns of Prescribing and Monitoring of Palbociclib NCT03285568	Rush University Medical Center	—
Unknown	Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Pati NCT02175446	Consorzio Oncotech	Phase 2
Terminated	A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Bre NCT01905592	Tesaro, Inc.	Phase 3
Terminated	GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast NCT01918306	Vanderbilt-Ingram Cancer Center	Phase 1 / Phase 2
Completed	Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer NCT01934478	Qingdao Central Hospital	—
Completed	Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer NCT01548677	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2
Unknown	Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients NCT01779531	Guangdong Academy of Medical Sciences	—
Terminated	Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer NCT01394211	University of Arizona	Phase 2
Completed	Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer NCT01288261	University of Arizona	Phase 1
Completed	8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer NCT01935492	Borstkanker Onderzoek Groep	Phase 3
Completed	Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastat NCT01885013	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Phase 2